Market Overview

Sorrento Therapeutics Has $4B Coronavirus Opportunity, Analyst Says

Sorrento Therapeutics Has $4B Coronavirus Opportunity, Analyst Says

Sorrento Therapeutics Inc's (NASDAQ: SRNE) coronavirus program has been met with equal optimism and skepticism, which has led to wild swings in its stock price.

The Sorrento Analyst

Dawson James Securities analyst Jason Kolbert initiated coverage of Sorrento with a Buy rating and a $24 price target.

The Sorrento Thesis

Sorrento is proceeding with the goal of generating an antibody cocktail against SARS-CoV-2 coronavirus infection, which could remain effective even if virus mutations occur, Kolbert said in a Tuesday note.

The analyst expects STI-1499 – Sorrento's first antibody in the planned antibody cocktail dubbed COVIDSHIELD – to move rapidly to commercialization, thanks to the U.S. Project Warp Speed.

While the antibody showed 100% inhibition in early studies, the low dose suggests the antibody "fits" its target extraordinarily well and, as such, can work at a very low dose, Kolbert said.

The analyst noted the company plans to engage with the regulators to determine the best pathway to make any potential treatment available as soon as possible. The company's management indicated it's well within its reach to produce tens of millions of doses in a short period of time to meet the vast projected demand.

"If we assume pricing below Remdesivir ($4k) and a million doses equals a $4 billion opportunity for this potential antidote," Kolbert said.

SRNE Price Action

Sorrento shares were up 4% to $5.27 at time of publication.

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

Latest Ratings for SRNE

May 2020Dawson JamesInitiates Coverage OnBuy
Mar 2020H.C. WainwrightReiteratesBuy
Oct 2019JMP SecuritiesInitiates Coverage OnMarket Outperform

View More Analyst Ratings for SRNE
View the Latest Analyst Ratings


Related Articles (SRNE)

View Comments and Join the Discussion!

Posted-In: Coronavirus Covid-19Analyst Color Biotech Price Target Initiation Analyst Ratings General Best of Benzinga

Latest Ratings

CREECanaccord GenuityReiterates72.0
AMTDWells FargoMaintains37.0
SWCHWells FargoMaintains20.5
SFWells FargoMaintains44.0
WBAB of A SecuritiesMaintains40.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at